The assay was established using high-grade serous ovarian cancer samples for which BRCA1 and BRCA2 mutation status as well as Myriad MyChoice homologous repair deficiency (HRD) status was known. The gene discussed is BRCA2; the disease is hypoparathyroidism-retardation-dysmorphism syndrome.